Literature DB >> 2251261

v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid.

A Leder1, A Kuo, R D Cardiff, E Sinn, P Leder.   

Abstract

Experimental carcinogenesis has led to a concept that defines two discrete stages in the development of skin tumors: (i) initiation, which is accomplished by using a mutagen that presumably activates a protooncogene, and (ii) promotion, which is a reversible process brought about most commonly by repeated application of phorbol esters. We have created a transgenic mouse strain that carries the activated v-Ha-ras oncogene fused to the promoter of the mouse embryonic alpha-like, zeta-globin gene. Unexpectedly, these animals developed papillomas at areas of epidermal abrasion and, because abrasion can also serve as a tumor-promoting event in mutagen-treated mouse skin, we tested these mice for their ability to respond to phorbol ester application. Within 6 weeks virtually all treated carrier mice had developed multiple papillomas, some of which went on to develop squamous cell carcinomas and, more frequently, underlying sarcomas. We conclude that the oncogene "preinitiates" carrier mice, replacing the initiation/mutagenesis step and immediately sensitizing them to the action of tumor promoters. In addition, treatment of the mice with retinoic acid dramatically delays, reduces, and often completely inhibits the appearance of promoter-induced papillomas. This strain has use in screening tumor promoters and for assessing antitumor and antiproliferative agents.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2251261      PMCID: PMC55127          DOI: 10.1073/pnas.87.23.9178

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Developmental biology. Reading the retinoid signals.

Authors:  J Brockes
Journal:  Nature       Date:  1990-06-28       Impact factor: 49.962

Review 2.  Hereditary anemias of the mouse: a review for geneticists.

Authors:  E S Russell
Journal:  Adv Genet       Date:  1979       Impact factor: 1.944

3.  Tumor promotion and the induction of epidermal ornithine decarboxylase activity in mechanically stimulated mouse skin.

Authors:  I Clark-Lewis; A W Murray
Journal:  Cancer Res       Date:  1978-03       Impact factor: 12.701

4.  The function and mechanism of promoters of carcinogenesis.

Authors:  R K Boutwell
Journal:  CRC Crit Rev Toxicol       Date:  1974-01

5.  Development of the mouse hematopoietic system. I. Types of hemoglobin produced in embryonic yolk sac and liver.

Authors:  J E Barker
Journal:  Dev Biol       Date:  1968-07       Impact factor: 3.582

6.  Phorbol diester receptor copurifies with protein kinase C.

Authors:  J E Niedel; L J Kuhn; G R Vandenbark
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

7.  Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters.

Authors:  M Castagna; Y Takai; K Kaibuchi; K Sano; U Kikkawa; Y Nishizuka
Journal:  J Biol Chem       Date:  1982-07-10       Impact factor: 5.157

8.  Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogene.

Authors:  A Balmain; I B Pragnell
Journal:  Nature       Date:  1983 May 5-11       Impact factor: 49.962

9.  Glucocorticoid regulation of the Ha-MuSV p21 gene conferred by sequences from mouse mammary tumor virus.

Authors:  A L Huang; M C Ostrowski; D Berard; G L Hager
Journal:  Cell       Date:  1981-12       Impact factor: 41.582

10.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

View more
  61 in total

1.  Defining the minimal length of sequence homology required for selective gene isolation by TAR cloning.

Authors:  V N Noskov; M Koriabine; G Solomon; M Randolph; J C Barrett; S H Leem; L Stubbs; N Kouprina; V Larionov
Journal:  Nucleic Acids Res       Date:  2001-03-15       Impact factor: 16.971

Review 2.  The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses.

Authors:  A M Schmidt; S D Yan; S F Yan; D M Stern
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

3.  A global collaboration on carcinogenicity screening in transgenic mouse models.

Authors:  R Forster
Journal:  Transgenic Res       Date:  1998-11       Impact factor: 2.788

Review 4.  Retinoid pathway and cancer therapeutics.

Authors:  Nathan Bushue; Yu-Jui Yvonne Wan
Journal:  Adv Drug Deliv Rev       Date:  2010-08-03       Impact factor: 15.470

5.  CCAAT/enhancer binding protein-beta is a mediator of keratinocyte survival and skin tumorigenesis involving oncogenic Ras signaling.

Authors:  Songyun Zhu; Kyungsil Yoon; Esta Sterneck; Peter F Johnson; Robert C Smart
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-26       Impact factor: 11.205

6.  E2F1 has both oncogenic and tumor-suppressive properties in a transgenic model.

Authors:  A M Pierce; R Schneider-Broussard; I B Gimenez-Conti; J L Russell; C J Conti; D G Johnson
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

7.  Cellular aging is a critical determinant of primary cell resistance to v-src transformation.

Authors:  N Tavoloni; H Inoue
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

8.  Myeloid-derived suppressor cells in the development of lung cancer.

Authors:  Myrna L Ortiz; Lily Lu; Indu Ramachandran; Dmitry I Gabrilovich
Journal:  Cancer Immunol Res       Date:  2013-10-18       Impact factor: 11.151

Review 9.  Transgenic mice and squamous multistage skin carcinogenesis.

Authors:  K Brown; A Balmain
Journal:  Cancer Metastasis Rev       Date:  1995-06       Impact factor: 9.264

Review 10.  Transgenic and gene knockout mice in cancer research.

Authors:  J L Viney
Journal:  Cancer Metastasis Rev       Date:  1995-06       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.